Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 13/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085757 | 0.85 | PIK3CD (0.42) | GRIA1PDE3BPDE3ACACNG8 | |
| SCHEMBL20085510 | 0.85 | PDE3B (0.41) | GRIA1PDE3BPDE3APGR | |
| SCHEMBL20085518 | 0.85 | GRIA1 (0.39) | GRIA1PDE3BPDE3APGR | |
| SCHEMBL20120114 | 0.73 | HTR2A (0.31) | — | |
| SCHEMBL20120025 | 0.73 | — | — | |
| SCHEMBL20085484 | 0.72 | PIK3CD (0.45) | GRIA1PDE3BPDE3ACACNG8 | |
| SCHEMBL20085659 | 0.71 | MET (0.43) | GRIA1PDE3BPDE3ACACNG8 | |
| SCHEMBL20120026 | 0.70 | PTGS2 (0.33) | — | |
| SCHEMBL20085886 | 0.70 | GRIA1 (0.39) | GRIA1CACNG8 | |
| SCHEMBL20085786 | 0.70 | MET (0.41) | GRIA1PDE3BPDE3ACACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111925-A1 | 3-ARYL-2H-PYRAZOLO[4,3-b]PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111925-A1 | 3-ARYL-2H-PYRAZOLO[4,3-b]PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN3B, GRIN2B | GRIA1 41/4885PDE3B 716/4885PDE3A 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.